Company
Intervacc AB
Headquarters: Hagersten, Sweden
Employees: 12
CEO: Mr. Andreas Andersson
Market Cap
kr479.4 Million
SEK as of Jan. 1, 2024
US$47.6 Million
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $461.52 B |
| Vertex Pharmaceuticals Incorporated | $107.23 B |
| Regeneron Pharmaceuticals, Inc. | $100.01 B |
| CSL Limited | $94.74 B |
| Marinomed Biotech AG | $73.23 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Intervacc AB (publ), a biotechnology company, engages in the research and development of veterinary vaccines using recombinant proteins for animal health. It offers vaccines, pharmaceuticals, and vitamins for horses, piglets, and cows. The company also provides veterinary bacteriological and mycological analyses for veterinarians and animal hospitals. It serves customers in Nordic countries and the Baltic states. Intervacc AB (publ) holds an agreement with the Swedish University of Agricultural Sciences, SLU for the development of animal health vaccines. The company has a collaboration with the Karolinska Institute. The company is based in Hägersten, Sweden.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Intervacc AB has the following listings and related stock indices.
Stock: OMX: IVACC wb_incandescent
Stock: FSX: 2000000000 wb_incandescent